MEDICATION REFERENCE · REVIEW DRAFT
Wegovy: source schedule reference
Research reference only. Source-reported examples and schedules are not dosing recommendations from MGMT Research. They do not establish safety or suitability. Prescribed medication decisions belong with a licensed clinician and the current product label.
Reference notes
Wegovy is a branded semaglutide product. This page records the source schedule for review; it does not prescribe a dose or equate an MGMT research vial with the branded medicine.
The source lists weekly doses of 0.25, 0.5, 1.0, 1.7, 2.4 mg. It describes increases about every 4 weeks.
Wegovy is a trademark of Novo Nordisk; MGMT does not claim manufacturer affiliation.
| Vial | Diluent | Target | Volume | U-100 units |
|---|---|---|---|---|
| 5 mg | 2 mL | 250 mcg | 0.10 mL | 10 |
Source & content review 3 notes
This is an original, concise draft. Full information and numerical parity with the source is not yet established.
Open source reference ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source is a secondary summary; current product presentation, indication and prescribing details must be reconciled with the official label before publication.
- Source treats 2.4 mg as the upper Wegovy schedule. Current manufacturer PI search also lists WEGOVY HD 7.2 mg and tablets; source scope is incomplete. Preserve source values pending explicit approval. Primary: https://www.novo-pi.com/wegovy.pdf
Captured source values
{
"numericalFacts": []
}